Connect with us

Business

CureVac Stock Could Fall Even Further After Vaccine News – Barron’s

The German biotech reported disappointing results from a late-stage trial of a Covid-19 vaccine. The stock lost nearly half of…

Published

on

Article feature image
ADVERTISEMENT

Wall Street analysts are taking a far more pessimistic view of CureVac as the stock tumbles after the German biotech reported disappointing results from a late-stage trial of a Covid-19 vaccine on Wednesday.
In a note out Thursday, Guggenheim analyst Seamus…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Spirit Airlines cancels 60% of scheduled flights on third day of “operational issues” – CBS News
Article feature image
Feds look to speed up full approval of Pfizer vaccine – New York Post
Article feature image
Charts suggest the stock market is getting close to a near-term top, Cramer says – CNBC